Why Investors Should Care About Menopause

Happy 40th birthday. Welcometo your first (of many) perimenopause ads. Bone density? Brain fog? Hormonetherapy?

Not long ago, there weren'tmany answers. Just ask your mother.

We've come a long way. Westill have far to go.

Menopause Is Finally Having It's Moment

For decades, women were toldto push through menopause in silence, with few solutions designed for them.That silence is breaking, and the market is responding.

Approximately 1.3 million U.S. womenenter the menopause transition each year, and by 2030, 1.2 billionwomen worldwide will be in some stage of the transition. Yet as recently as 2021,only about 5% of femtechstartups addressed menopause.

Today, the landscape looksvery different. SJF Ventures' grid maps roughly 50 menopause companies acrossvirtual care, consumer products, digital tools, biopharma, and devices. And2025–2026 delivered three signals investors can't ignore:

• Regulation shifted. In November 2025, the FDAannounced it would remove the "blackbox" warning from menopausal hormone therapy, and it approved the updatedlabeling in early 2026. Two decades of fear around HRT is giving way to informed choice.

• New therapies arrived. Bayer's Lynkuet (elinzanetant)was FDA-approved in October 2025 as a hormone-free option for hot flashes, joining Astellas'Veozah.

• A category leader emerged. Midi Health raised a $100 million Series D inFebruary 2026 at a valuation above $1 billion, becoming menopause care's first unicorn.

From One Moment to a Continuum

Menopause is not one stage.It is a continuum that can span decades.

• Perimenopause often begins in the 40s, with irregular cycles, mood changes, andsleep disruption. At-home hormone tracking, digital tools, and lifestylesupport make earlier recognition and management possible.

• Menopause brings acute issues like hot flashes, cognitive shifts, andmetabolic changes. Solutions now span hormone therapy, new non-hormonal drugs,devices, and supplements.

• Post-menopause shifts the focus to longevity. Bone density, cardiovascularhealth, and cognitive function come to the forefront, linking menopausedirectly to the healthy-aging movement.

Investors who treatmenopause as a single moment will miss the richness of this continuum. Thosewho build for each stage will earn deeper loyalty and trust.

‍

Innovation Takes Shape

The category is maturing,with clear leaders, fresh entrants, and the first real exits.

• Virtual + Hybrid Care: Midi Health now serves more than 25,000patients a week with insurance-covered care. Alloy has taken a leaner path, reaching profitability on roughly $21 million raised. Elektra Health partnered with Oscar Health on HelloMeno, a menopause-focused ACA marketplace plan, and Visana Health closed a $24 million Series A with backing from The Cigna Group Ventures. Evernow and Halle Berry's Respin round out a crowded, fast-moving field.

• Consumer Products: Brands such as Womaness,Kindra, Stripes Beauty, and Winona are building targeted solutions acrosssupplements, intimate care, and skin and body care. Retail is leaning in: NaomiWatts' Stripes expanded from afour-store pilot to 448 Ulta Beauty locations in July 2026, and Womaness has a dedicated, merchandisedpresence at Ulta.

• Digital Technology: Apps like Balance(from Dr. Louise Newson), Caria, andPeanut track symptoms, deliver guidance, and connect women to community and care.

• Biopharma: Alongside Bayer and Astellas, whose Veozah generated anestimated $230–240 million inin-market sales in the first three quarters of its FY2025, Gameto raised a $44 million Series C and received an ARPA-Haward to develop an implantable cell therapy for menopause. Ovarian-agingpioneer Oviva Therapeutics was acquired by Granata Bio in April 2026.

• Medical Devices: Boston's own Embr Labstargets hot flashes with its wrist-worn thermal device. Osteoboost offers the first FDA-cleared,non-drug treatment for osteopenia in postmenopausal women. Mira brings at-home hormone monitoring to perimenopause, and Madorra has FDA breakthrough device designation for a non-hormonal vaginalatrophy treatment.

‍

Thanks to SJF Ventures for this grid:

‍

‍

The Market Opportunity with an Investor Lens

The financial potential is clear and it's growing steadily.

The U.S. menopause market is estimated at roughly $5.8 billion in 2025 to $6.2 billion, depending on scope, with forecasts reaching about $8 billion or more in the early 2030s. Globally, estimates put the market at about [$18–19 billion in 2025], rising to roughly $29 billion bythe mid-2030s.

And the cost of doing nothing is significant: untreated menopause symptoms cost an estimated $25 billion a year in U.S. medical expenses and lost productivity.

Funding tells a more nuanced story. PwC estimates approximately $1.7 billion was invested in menopause-focused companies from 2020 through 2025, well above the roughly $530 million SJF Ventures tallied through early 2023. Across women's health overall, venture investment dipped in 2025 from the2024 record, with SVB projecting a rebound in 2026.

But the money is highly concentrated. Midi Health alone accounts for about 73% of publicly disclosed funding for U.S. menopause-specialist care companies. For investors, that concentration isn't a warning sign. It's white space.

Celebrity and cultural momentum continue to build. Amy Schumer, Tory Burch, Sheryl Sandberg, Connie Britton, and Brandi Chastain joined Midi Health's $63 million Series B, and Serena Williams' Serena Ventures join edits Series D.

Why Investors Should Move Now

Why Investors Should Move Now

Menopause solutions combine recurring revenue with strong retention, and they expand naturally into sleep, sexual wellness, mental health, weight management, and longevity.

Exit pathways are no longer theoretical. Pharmavite acquired Bonafide for $425 million, Nameless CPG acquired Wile, and consolidation is underway across care delivery and biotech.

Employers are moving too.According to SHRM's 2026 EmployeeBenefits Study, 27% of employers now offer menopause support, up from 18% just ayear earlier.